See more : Mytilineos S.A. (MYTHY) Income Statement Analysis – Financial Results
Complete financial analysis of Tyme Technologies, Inc. (TYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyme Technologies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Wellbiotec Co., Ltd. (010600.KS) Income Statement Analysis – Financial Results
- PT. Clipan Finance Indonesia Tbk (CFIN.JK) Income Statement Analysis – Financial Results
- Boral Limited (BLD.AX) Income Statement Analysis – Financial Results
- Monolithic Power Systems, Inc. (MPWR) Income Statement Analysis – Financial Results
- SJM Co., Ltd. (123700.KS) Income Statement Analysis – Financial Results
Tyme Technologies, Inc. (TYME)
About Tyme Technologies, Inc.
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.44M | 17.03M | 12.96M | 14.72M | 8.84M | 6.11M | 3.82M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Other Expenses | 2.44M | 0.00 | 0.00 | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.20K |
| Operating Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | -2.10K |
| Cost & Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | 2.10K |
| Interest Income | 0.00 | 22.08K | 229.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 70.24K | 97.13K | 114.24K | 0.00 | 0.00 | 0.00 | 3.50M | 76.56K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.96M | 5.18K | 5.18K | 8.42K | 4.30K | 4.28K | 4.29K | 76.56K | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.56M | -27.22M | -25.76M | -31.78M | -19.36B | -15.21B | -8.60M | 22.65K | -56.59K | -27.43K | -2.10K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -25.51M | -27.22M | -25.76M | -31.78M | -19.36M | -15.21M | -8.60M | -53.91K | -56.59K | -27.43K | -2.10K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.89M | -1.76M | 3.76M | -1.21M | 19.34B | 15.19B | -3.13M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -23.63M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.96M | -1.66M | 3.87M | -1.21M | 390.39K | 0.00 | 376.26K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -21.67M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
| Weighted Avg Shares Out (Dil) | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
Tyme Technologies Stock Rallies: A Technical Analysis
TYME Stock: The Cancer Treatment News That's Boosting Tyme Today
Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
Best Biotech Penny Stocks to Buy? 3 to Watch Before Monday
Tyme Stock Is Trading Higher On Pipeline Update After Strategic Review, Q4 Earnings
Tyme Technologies, Inc. (TYME) CEO Richie Cunningham on Q1 2021 Results - Earnings Call Transcript
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results
3 Biotech Penny Stocks That Are Popular on Reddit Right Now
Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount
Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List
Source: https://incomestatements.info
Category: Stock Reports